For the first time in the world, an innovative and unique testing tool has been developed by doctors from India that can assess the improvement in patients with Cerebral Palsy (CP), a disorder caused due to brain damage that affects a person’s muscle tone, movement, and motor skills.

The tool is a one of its kind invention, as it has far more evaluation parameters compared to the existing system.
With the help of a numeric scoring system, it also has the advantage of revealing even the slightest improvement in CP patients.

Its developer, Dr Geeta Shroff is the founder and medical director of Nutech Mediworld, the first and only facility in the world to offer human embryonic stem cell therapy.

Aditya Jyot Eye Hospital, Mumbai’s only NABH accredited eye hospital and one of the most respected eye surgery and vision correction centers, has undertaken a huge technological leap. The hospital that has been of offering LASIK or laser based vision correction surgery, has upgraded its system to significantly reduce surgery time, increase surgical efficiency and expedite the healing process… so much so that now you can undergo a painless, bloodless eye surgery in the amount of time it takes for you to have a cup of coffee!

Laser based surgeries are used to set right some of the most complicated vision problems and are a boon to those who wish to do away completely with wearing spectacles or lenses. It can correct powers as high as -10. To make these surgeries even more efficient and comfortable for the patient, Aditya Jyot Eye Hospital has switched to the internationally respected Alcon EX 500 Laser for conducting LASIK surgeries.

This machine is superior to other alternatives available today as it reduces corneal dehydration to increase outcome accuracy. Each burst of the laser lasts for a billionth of a second before the laser moves to its next position at a speed 100 times that of other lasers.

The Alcon EX 500 Laser uses a small-spot laser beam, which allows LASIK specialists to shape the cornea in finer, more gradual increments for a smoother surface with eye-tracking technology 8 times faster than some of the competition.

Alcon EX 500 Laser’s integrated cross-line projector provides the surgeon with an exact alignment of the head’s and eye’s position by generating a red-light cross on the eye for accuracy.

Using advanced Wavefront Optimized ® technology, the Alcon EX 500 Laser creates a “map” of your eyes and their unique characteristics to assist your surgeon in creating a personal vision profile for you.

This map serves as a guide that helps doctors locate the eye’s exact treatment position, which is one of the most important factors in obtaining a more naturally shaped cornea and therefore an excellent refractive outcome, especially when correcting eyes with high astigmatism.

All these technological improvements contribute to reducing the actual surgery time to nearly half that of an average LASIK surgery. The procedure is painless and bloodless. The patient needs to rest for just 48 hours and stay out of direct sunlight, dust and heat during this period. After this they can go back to their everyday life.

“The WaveLight EX500 facilitates fastest treatment times and a complete, safe, patient specific and customized Laser Vision Correction. It is this attitude which has helped us build a stable relationship of trust with our patients. Their implicit faith, gratitude and referrals are the measures of our success” says Dr. Kavita Rao, Head, Cornea and Refractive Services.

In support of its mission to help the world run better and improve people’s lives, SAP AG (NYSE: SAP) recently announced that it will work globally with Specialisterne to employ people with autism as software testers, programmers and data quality assurance specialists.

SAP sees a potential competitive advantage to leveraging the unique talents of people with autism, while also helping them to secure meaningful employment.

It is estimated that one percent of the world’s population is affected by autism (Autism Spectrum Disorder).

Specialisterne is an internationally recognized leader in harnessing the talents of people with autism to work in technology-oriented jobs such as software testing, programming and data management.

Originally founded in Denmark, Specialisterne has operations around the world, including offices in the U.S., UK, Ireland, Austria, Switzerland, Germany, Norway, Iceland and Poland.

As part of the partnership, Specialisterne will extend its operations to support SAP’s global expansion of the program over the next several years.

The global announcement follows successful pilot projects in India and Ireland that demonstrate the positive impact of empowering people with autism to excel in their areas of strength.

Working locally with Specialisterne, SAP® Labs in India hired six people with autism as software testers for SAP® Business Suite applications. As a result, the team has increased their productivity and cohesiveness in key areas.

The Ireland pilot is currently completing the screening phase for five positions to be filled this year. SAP will expand the program globally, starting in the U.S., Canada and Germany in 2013.

At SAP, an inclusive and diverse environment promotes a culture that enables employees to find innovative solutions to challenges facing customers as well as society as a whole.

Furthering its engagement with the local community of people and families affected by autism, SAP Labs in India recently developed a consumer iPad application called “Bol” to assist with the education of children with autism.

This innovative learning program helps children learn and comprehend simple, everyday objects and processes, using auditory, visual and instant feedback functions.

Public-Private Partnership Announces Phase III Clinical Trial Results at Conference in Delhi

New Delhi, India—The Government of India’s Department of Biotechnology (DBT) and Bharat Biotech announced positive results from a Phase III clinical trial of a rotavirus vaccine developed and manufactured in India. Data from the trial, presented today at the International Symposium on Rotavirus Vaccines for India—The Evidence and the Promise,showed ROTAVAC®to have an excellent safety and efficacy profile.

The clinical study demonstrates for the first time that the India-developed rotavirus vaccine ROTAVAC®is efficacious in preventing severe rotavirus diarrhoea in low-resource settings in India. ROTAVAC®significantly reduced severe rotavirus diarrhoea by more than half—56 percent during the first year of life, with protection continuing into the second year of life. Moreover, the vaccine also showed impact against severe diarrhoea of any cause.

“This is an important scientific breakthrough against rota-virus infections, the most severe and lethal cause of childhood diarrhoea, responsible for approximately 100,000 deaths of small children in India each year,” said DBT Secretary Dr K. Vijay Raghavan. “The clinical results indicate that the vaccine, if licensed, could save the lives of thousands of children each year in India.”

The vaccine was developed through a unique social innovation partnership that brought together the experience and expertise of Indian and international researchers as well as the public and private sectors. The vaccine originated from an attenuated (weakened) strain of rotavirus that was isolated from an Indian child at the All India Institute of Medical Sciences in New Delhi in 1985-86. Since then, partners have included DBT, Bharat Biotech, the US National Institutes of Health (NIH), the US Centers for Disease Control and Prevention (CDC), Stanford University School of Medicine, and the nongovernmental organization, PATH. Dr M.K. Bhan, who recently completed his service as DBT Secretary, was tireless in fostering the social innovation partnership and ensuring the highest standards for the vaccine.

The randomized, double-blind, placebo-controlled Phase III clinical trial enrolled 6,799 infants in India (aged six to seven weeks at the time of enrolment) at three sites—the Centre for Health Research and Development, Society for Applied Studies (SAS) in New Delhi; Shirdi Sai Baba Rural Hospital, KEM Hospital Research Centre in Vadu, Pune; and Christian Medical College (CMC) in Vellore. The Clinical Operations Management Unit headed by Dr Nita Bhandari at SAS oversaw the day-to-day coordination and logistical complexities of this multi-site study and played a pivotal role in the conduct of this trial. The Principal Investigators were Dr Temsunaro Rongsen-Chandola at SAS, Dr Ashish Bavdekar at KEM, and Dr Gagandeep Kang at CMC.

The Data Safety Monitoring Board (DSMB), an independent group of experts established to protect the participating infants’ rights and needs during the Phase III trial, determined that the trial met the highest standards for ethics and patient care and complied with international standards for good clinical practices.

Bharat Biotech previously announced a price of US$ 1.00/dose (or approximately INR 54/dose) for ROTAVAC®and will soon file for registration of the vaccine in India. If licensed by the Drugs Controller General of India (DCGI), the vaccine will be a more affordable alternative to the rotavirus vaccines already on the market.

“With its low price and strong efficacy, ROTAVAC®has the potential to significantly reduce the incidence of severe diarrhoea due to rotavirus among children in India,” said Dr M.K. Bhan, Advisor to the Indian Academy of Pediatrics and former DBT Secretary.
The vaccine efficacy compares favorably with the efficacy of the currently licensed rotavirus vaccines in low-resource countries. The study results showed clear evidence of protection across different rotavirus strains and continued efficacy in the second year of life.

Infants enrolled in the study received ROTAVAC®and the Universal Immunization Programme (UIP) vaccines, including oral polio vaccine (OPV). When the immune responses to OPV were tested, the result showed that infants receiving OPV at the same time asROTAVAC® generated comparable immune responses to all three polio serotypes as the infants receiving OPV without ROTAVAC®;this result supports the concurrent administration of OPV and ROTAVAC®.

“Vaccines work to save and protect children from diseases like rotavirus for a lifetime,” said Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation. “This public-private partnership is an exemplary model of how to develop affordable technologies that save lives.”

The vaccine development partnership was supported by DBT, the Bill & Melinda Gates Foundation, the Research Council of Norway, and the UK Department for International Development. Bharat Biotech invested important technical, manufacturing, and financial resources towards vaccine development. ROTAVAC®is an oral vaccine and is administered to infants in a three-dose course at the ages of 6, 10, and 14 weeks. It is given alongside routine immunizations in the UIP vaccines recommended at these ages.

“ROTAVAC® represents the successful research and development of a novel vaccine from the developing world with global standards,” said Dr Krishna M. Ella, Chairman and Managing Director of Bharat Biotech. “ROTAVAC®is a testament of our strong vision and commitment to develop affordable health care solutions for infectious diseases—we are proud, yet humbled by our contribution to this social innovation project and global public health priority. We are thankful to all the partners in the Rotavirus Vaccine Development Project—DBT, the Indian Council of Medical Research, PATH, the Bill & Melinda Gates Foundation, NIH , CDC, and Stanford University—for their valuable support in this unique international public-private partnership.”

Prior to conducting the study, the investigators received approvals from the DCGI, the Institutional Review Board for DBT, and the ethics review committees of each study site. The study partners also consulted with the State Governments of Delhi, Maharashtra, and Tamil Nadu, as well as the Ministry of Health and Family Welfare. In addition, the study was approved by the Western Institutional Review Board in the United States and met the highest international clinical trial standards. The DSMB strictly monitored the trial throughout for adherence to these standards and protocols. The trial design included a strong safety net to identify and treat illnesses, especially gastroenteritis, among study infants as early as possible. All of the infants enrolled in the trial received high-quality medical and emergency care during the trial period.

The support laboratory was the Translational Health Science and Technology Institute with Dr Sudhanshu Vrati as the lead. Quintiles was responsible for several aspects of the trial including medical monitoring, data management, site monitoring, pharmacovigilance, and biostatistics. Good Clinical Practice compliance of the clinical trials was audited by ANTHA Clinical Quality Assurance.

Courtesy :

Applying mustard oil in hair will effectively control hairfall and make the hair look shinny and healthy.

Varun and his wife has just returned home. They had gone to see a cardiac surgeon. Varun was experiencing a fluctuating blood pressure, headache, vomiting and a kind of depression for the past few days.

The doctor’s diagnosis was a bolt from the blue for his family. The doctor has sternly suggested him either to stop drinking or be prepared with INR 50 lakhs for undergoing a liver transplant surgery very soon.

Today a sense of gloom prevail in each and every corner of their home.

Varun who migrated to Delhi from Assam for a better job opportunity around a decade back was working in a multinational company. His family was happy that he could find himself a good job. But continuous graveyard shifts left Varun with hardly any time to interact with his family members. They had absolutely no knowledge of his drinking habits. His health conditions deteriorated to the extent that he had to ultimately quit his job.

Varun’s family is just an example. There are hundreds and thousands of families in India that meet with similar fate.

According to a study by World Health Organisation on alcohol and health 2.5 million people die every year.

Today, Varun’s elder brother Tarun has taken up the responsibility of solely taking care of the family of six including Varun’s five year old son.

Varun is not alone. People across the globe are victims of alcohol addiction.

According to the global status report by WHO, globally, 6.2 per cent of all male deaths are related to alcohol compared with 1.1 per cent of female deaths.

India accounts for 22.5 percent of the total alcohol consumption.

Alcohol related deaths are increasing at a rapid pace. The main reason being, injuries in a drunken state, cancer, cardiovascular diseases and liver cirrhosis.

Again, the onset of depression is a common symptom among alcohol addicts.

In India an estimated 80 percent of alcohol consumption is in the form of hard liquor or distilled spirits. That is, addicts in our country are more into drinks that are concentrated with alcohol.

India is the largest consumer of whiskey across the globe. According to the study, the estimated whiskey market in India by the end of 2013 is expected to be us $10 billion or INR 541.389 billion. Thanks to the growing economy of the country.

India is a union of 28 states and seven union territories. The drinking age and norms vary from state.

Drinking alcohol above the limit is a menace in most of the household and for the health authorities. News of hooch tragedy, wherein death due to country made spurious liquor is common in India.

A few Indian states like Gujarat, Mizoram, Manipur, Nagaland has put a total ban on liquor.

Taxes generated from alcohol production and sale which is estimated to be at INR 25,000 crore is the major source of revenue in most states. And that is the reason that the states have been given a permit for alcohol sale.

Though a large amount of revenue is generated from the sale of alcohol, the hidden cost of healthcare etc is seen to exceed the revenue generated.

The crux is that as long as we take the path of something called responsible drinking, we will keep spending a major amount of our income in treatment, thereby creating unrest in the family as well as the larger well being as a whole.

Courtesy : Statistical Data’s …. thanks to World Health Organisation

Vitamin Enriched Water Drink “WILD WATER” Launched
Product Of Beltek Canadian Water Limited Offers Three Flavors
Signs Shazan Padamsee as Brand Ambassador

“WILD WATER”, a first of its kind Vitamin enriched Water has been introduced by Beltek Canadian Water Limited. With the launch of this Life style beverage, the company has introduced an entirely new category in the Indian functional Drink Category.

With Natural Flavours, Natural Colours, No preservatives Low Sugar and the goodness of Vitamins Wild Water focuses on tasty hydration and meeting the needs of calorie-conscious consumers. The drinks are available in three flavors which include Tropical Citrus, flavoured Energise, Lemon flavoured Reload and Dragon Fruit flavoured Immunity

“Our natural flavored water with the goodness of Vitamins has opened a completely new Category in the Rs.300 crore functional drink market (excluding energy drink)”, said Mohit Verma, Director, Beltek Canadian Water Limited.

While Tropical Citrus flavoured Energise comes with the benefit of Vitamins C & B along with Guarana extracts, Lemonade flavoured Reload is available with the benefits of Vitamins A, B & C along with electrolytes and the Dragon Fruit flavoured Immunity with Vitamin B, C & Zinc.

With no seasonality factor the all weather Lifestyle Drink Wild-Water not only provides a dose of vitamins it is also prepared with finest ingredients from USA, contains mouth-watering flavours that shine through as well as maintains International Quality Standard

“People these days demand more from a beverage. If you look back people moved on from CSD to juices and now are further shifting towards healthier, Less Calorie, and more natural alternatives. Therefore we see a positive future trend towards such categories.” Continued Steve Verma, Director, Beltek Canadian Water Limited.

“In India the consumers lack excess to all kind of functional beverages. The lack of product offerings has restricted the consumer to consume conventional carbonated and sugary drinks thereby not deriving any health related benefit from the beverage. Given the option, the consumers both in adult and children category are willing to try the functional beverage, which besides giving hydration have positive effect on quality of life”, further continued Rohit Verma, Director who thought of the idea of a Vitamin based Beverage for the Indian consumers.

Each batch of Wild Water undergoes a rigorous test procedure to maintain International Standard quality and excellence. The concoction has been formulated with the least possible amount of Pure Cane Sugar, is an excellent healthy alternative to sweetened juices, colas and fizzy drinks.

Available at an attractive Price of Rs 70, Wild Water is already present in leading stores of Delhi/ NCR and soon will be entering other Indian cities. The company has signed upcoming Indian film and stage actor Shazahn Padamsee as the Brand ambassador Wild Water.

About Beltek Canadian Water Limited
Beltek Canadian Water Limited is the market leader in the business of Bulk Water in Delhi/ NCR. The company has been in the beverage business for almost two decades started as an equity Joint venture with Prime water Canada in the year 1995 for both 1 Liter and 20 Liter segments, one of the first movers in bulk water category in the country. The company became a franchisee of Pepsico for its water Brand Aquafina in 2003. For more details please visit


Best Western AVN Arogya To Give Boost to Medical Tourism in the Region


Madurai, Tamil Nadu:  Best Western India, with 41 hotels, in operation and under development in India, recently  announced the launch of the BEST WESTERN AVNArogya in Madurai, Tamil Nadu.  The new fully opened Best AVN Arogya is the result of a tie up between Best Western India and AVN Arogya & Ayurvedic hospital and aims to give a boost to Medical Tourism in the region. 


Sporting, contemporary furnishings the BEST WESTERN AVN Arogya features 20 tastefully done well appointed cottages & rooms with up-to two bedrooms with a private Jaccuzzi. A special feature for these room is the attached private therapy suites giving the discerning Best Western Traveller  not only privacy but also  the comfort of Home at the same time.   


 Mr. Sudhir Sinha, President and COO Best Western India while making the announcement said “This is a unique tie up in the region. The Best Western International standards and experience of over 4000 Hotels Worldwide and the AVN Arogya’s 80 Years experience in the Ayurvedic field offer a unique blend to attract International medical and wellness tourists to the region”


Dr. Ramesh R Varier, Mg. Director & Senior Physician, AVN Arogya Healthcare Ltd, continued  “

We are a integrated Hospital offering authentic Ayurveda Services in a resort ambience. This tie up of Hospitality and Health-care will help us reaching further to not only the vast Indian community across different parts but also to the International Audiences that the Best Western International presence in over 100 countries can provide”


The Best Western AVN Arogya offers Private luxury suites with two bedrooms and a private therapy suite and with a private Jacuzzi, Deluxe Villas accommodating up-to 4 persons with privacy for two person, with attached therapy suites, Classic Villas and Deluxe AC Rooms with attached therapy suites.


The three star category Best Western AVN Arogya also has Dhyana (Yoga Centre), Saffron- (Ayurvedic Restaurant), Tamarind  tree (The Garden Restaurant), Hotpot (Coffee Shop), Tejus ( Beauty Spa), Kaya (The Health Club), Vilasa (The indoor Games area), Apanika (The Gift & Boutique shop), Bodhini (The Library ), Sabha, (The Board Room), Indraprastha (The Banquet hall) along with an Organic  dairy & vegetable garden, Walking Track & Laundry facilities among others.


According to a study by PWC Wellness today is an INR 490 bn industry in India. However, it is still less than two per cent of the global wellness industry. Wellness services alone comprise 40% of this market. During the next three years we estimate that the Indian wellness industry will grow at a CAGR of 20% to reach INR 875 billion. Consumers and their needs will continue to evolve, driving the transition from remedial care to a more holistic view on preventive care. This augurs well for the wellness industry in India.


“This Tie up signifies that Best Western is the brand of choice internationally for accommodation as well as Health, fitness, and, treatments even in the midscale segment. Our rapid growth in India is a testament to the relevance of our brand in a fast growing economy like India. We are happy to announce its launch today, expanding our presence in the state of Tamil Nadu. We are sure this will only be the beginning of our expansion in this region” continued Mr Sinha


“We already cater to many International customers for our Ayurvedic Treatments and this association will help us in increasing our visibility and customer base further. Best Western follows global best practices and adheres to strict guidelines. Best Western properties stand for the best Hospitality and Quality which are essential for good business practice” continued Dr Varier


About AVN Arogya  

AVN  is one of the oldest Ayurvedic Centres in India,  founded and operated by a family of Ayurvedic physicians with over 80 years and three generations of experience. Spread over 15 Acres Best Western AVN Arogya is a unique Holistic Healthcare Village  of a  Healthcare Centre and a Resort  Offering  Holistic  Wellness Programs encompassing Ayurvedic therapies in Conjunction with Yoga, Meditation,  Wholesome diet, Naturopathy, Fitness programmes , Beauty therapies , Counselling  & Advice on lifestyle changes in a natural and serene atmosphere. For further details please visit


About Best Western India

Part of The World’s Largest Hotel Chain® Best Western in India is managed by Cabana Hotel Management Services Pvt. Ltd. The chain has a presence with forty two properties in operation and under development in India with Ajmer, Ambala, Amritsar (2), Baddi, Bhatinda, Dehradun (2), Gurgaon, Indore, Jaipur, Jalandhar, Kashipur, Katra, Lucknow, Manesar, Mahipalpur, New Delhi, Zirakpur (Chandigarh) (2), in the North; Bangalore (2), Hyderabad (2), Kakinada, Kodaikanal, Madurai, Ooty, Tirupati and Visakhapatnam in the South; Ahmedabad (2), Aurangabad, Goa (3), Mumbai, Navi Mumbai and Surat in Western India; and Bhubaneswar (2), Darjeeling, Jamshedpur and Kolkata (2) in Eastern India. For further details please visit


About Best Western International, Inc.

Best Western International, Inc. is THE WORLD’S LARGEST HOTEL CHAIN®, providing marketing, reservations and operational support to over 4,200* BEST WESTERN®, BEST WESTERN PLUS® and BEST WESTERN PREMIER® hotels in 100* countries and territories worldwide. Each Best Western-branded hotel is independently owned and operated. Having celebrated 65 years of hospitality in 2011, Best Western has grown into an iconic brand that hosts 400,000* worldwide guests each night. Equally committed to the business and leisure traveller, Best Western recently embarked on a mission to lead the hotel industry in customer care. World Vision is the charity of choice for Best Western in building the world’s biggest family, with our hotels and staff sponsoring children in need around the globe. Our partnerships with AAA/CAA, Michael Waltrip Racing™ and Harley-Davidson® help guests make the most of every trip. For the fastest way to a free night globally, join Best Western Rewards®. For more information or to make a reservation, please visit


The Indian Supreme Court rejected the appeal of the Novartis patent protection of the updated version dell’antitumorale Glivec.

Maharashtra, Mumbai, April 9, 2013: Here are the drugmakers in pole position to win market share that Novartis is likely to yield. Following the judgment of the Indian Supreme Court, which dismissed the appeal by Novartis for patent protection of Glivec (imatinib), it is natural to ask, what are the generic companies that could take advantage of this niche market opened by this decision.

Novartis, in India, is destined to lose a share of the market share of Glivec is confirmed by the first reactions of the Stock Exchange in Mumbai, the square in which the title of the Swiss giant has immediately yielded 6.8%. It would benefit especially Taj Pharmaceuticals, a leading Indian generic manufacturer, Celon Labs, Natco Pharma, Dr. Reddy, Miracalus Pharma, Cipla, Glenmark Pharmaceuticals, Ranbaxy (a subsidiary of Daiichi Sankyo) and Shantha Biotechnics.

The Indian generics giant ‘Taj Pharma’ CEO A.K.Singh said in an interview with Bloomberg “the decision will have a positive impact on drug affordability, accessibility and availability of this drug in India for cancer (myeloid leukemia) patents, as Glivec (imatinib) costs more than Rs.10 lacks for monthly treatment compared to Rs.10,000 for our generic imatinib tablets”. Further, emphasised that life saving drugs should not be sold at “unaffordable prices” in shed of “international patent protection” and “research innovation”, when the underlying motive is revenue; human life should be considered above these motives and the Indian court decision should be considered in favour of healthcare industry to serve human race. Moreover, Singh also supports the idea of open “international patent pool” for life saving drugs as proposed in EMA Committee 2010.

On the other hand, some manufacturers of generic imatinib listed on the stock market have gained ground on the Bombay Stock Exchange, which allows you to make a fairly accurate estimate of what the companies in pole position to win market share that Glivec “designer” is intended to give in the coming months. the first place there Taj Pharma and Natco Pharma, whose stock rebounded by 9.6 and 5.4% respectively, in third place Ranbaxy, which marked a 2.7%, and in fourth place Cipla, whose title was up 1, 2% on the Bombay Stock Exchange.

Companies that already placing imatinib equivalent in India will no doubt take advantage of the comparative advantage that is to be already on the market, but this does not preclude other generics also active in other countries of the world, they decide to expand or short to converge on Indian square. In addition to Sandoz, which belongs to the same Novartis, one of the manufacturers of generic drugs in its portfolio that imatinib can be mentioned, for example, Teva and Aurobindo.

Generics, India is its voice

The case of our riflemen to the arms race, the higher specific gravity claimed within the United Nations to the historic judgment against Big Pharma. India is dragging its feet on the international stage. And it does so with a strong position of respect not only from the economic point of view, but also for major social and health issues.

The story is well known: on April 1, the Indian Supreme Court dismissed the appeal by Novartis concerning patent protection of the updated version of Gleevec , the cancer drug used for the treatment of myeloid leukemia and other cancers. The drug costs about $ 2,600 per month, while its equivalent is available for just $ 175.

For the judges, the Glivec would not be a new “invention”, but only the reformulation of the ‘ imatinib , a molecule whose patent has expired. The judgment binds to the Indian Patent Act, as amended in 2005, according to which “new version of a drug can be patented only if it is shown to be greater therapeutic efficacy than previous versions, whose patent has expired.”


For years India has strongly sided with the right to health, and emerging local pharmaceutical industry, earning the reputation as the “pharmacy of the poor” through a law that allowed the massive commercialization by Indian companies of generic drugs at prices much lower than the equivalent “designer”. The judgment of 1 April seems to confirm this trend.

Under international pressure, India has revised the law to patents on medicines until 2005, but the new provisions related only to the molecules discovered after 1995. Novartis had patented a version of Glivec in 1993, after abandoning the development, but the Indian judges have held, in which the first version of the drug and later versions are not “quite different”, so that the next release does not deserve an independent patent.

In particular, in the jargon is called “evergreening” the practice Indian law intellectual property rights on drugs aims to tackle: it is the subtle improvements made ​​to a drug whose patent is about to expire, in order to extend the patent protection.

The judgment against Novartis is the latest in a series of defeats suffered by similar multinational pharmaceutical companies in India. In recent months, the Indian judges have revoked the patent on several drugs giants Pfizer and Roche, as the cancer drug Tarceva, which is “copied” from the Indian Cipla, in fact undermining their monopoly. The singular story of Nexavar, an expensive drug against kidney cancer and liver produced by Bayer. A few months ago, the Court of Appeal in India has given the green light for production by the Indian generic Natco Pharma, although the drug was still under patent. A decision on the grounds that the drug “was not accessible to the majority of patients.” In fact, the Indian judges have forced Bayer to grant the license to produce the drug in exchange for 6 percent of royalties. Bayer did not appreciate the judgment and has already been used.


The Basel pharmaceutical giant said the decision will have a negative impact on research and innovation in India, a country which “refuses to protect the patent for Glivec, although the drug is recognized worldwide and protected in almost forty states,” says Novartis said in a statement. Signal opposite reactions NGO Berne Declaration and Doctors Without Borders, according to which the judgment Glivec represents a significant victory for patients who live in the poorest countries on the planet.

Interviewed by, Assogenerici reserves the right to read the reasons for judgment before taking a position on the matter. Instead, according to Massimo Scaccabarozzi, a number of Farmindustria , “the judgment deteriorates kills innovation and research.” He adds: “For a molecule steps by the discovery, which is when you registered the patent, trade spend ten years. The coverage lasts for twenty years, but not from the entrance on the market, so it is already halved. Reduce it further means killing research. ”


The study “Global Pharmaceutical market report & forecast: 2012-2017″ , illustrates that the current pharmaceutical market amounted to almost 900 billion dollars a year but is expected to grow in the next five years at a rate of 5 per cent per annum and, in 2017, will amount to at least 1.1 trillion dollars. However, the demand for drugs will grow especially in emerging economies, whose incidence in the world market could increase from 15 to 30 percent. This is also due to the patent protection of many drugs worth $ 29 billion in 2013 and $ 40 billion in 2014. Most of the market for these brand-name drugs will be replaced with generic drugs, a significantly lower cost.

According to the newspaper “The Unit”, between 2005 and 2020, the FDA, the U.S. organization responsible to monitoring of drugs, authorized the sale of only 22 new drugs a year. The industries are struggling to innovate and seek to extend the patent expired in older drugs ritoccandoli in non-essential components.

Each new drug then loses value. The “golden age”, every new drug in five years hits the placing on the market produced $ 515 million, it now produces 430: a net loss of 15 per cent. And again, the companies in the first 5 years after the development of a new drug ricavavano $ 275 million for every billion dollars invested in research and development. Now we derive just 75 million. Loss of productivity is 70 percent. All the more serious when you consider that global investments in “research and development” on drugs has doubled in absolute terms, dropping from 65 to 125 billion dollars.


Thanks to India’s patent law, which since 1970 allowed India to produce generic versions of drugs still under patent abroad, the Indian pharmaceutical industry has become, with that of Brazil, the largest producer of generic drugs. This has led to significant benefits especially for the poorest countries in the world, where the cost of some therapies have been literally destroyed.

According to estimates by Doctors Without Borders, for example, thanks to antiretroviral Indians and the decision of the Brazilian government to produce generic drugs for AIDS, since 2000 the price of medicines against HIV fell by 99 percent, if in 2000 treating an AIDS patient with drugs “brand” was listed at $ 10,000 a year, now the cost of the same treatment with generics produced in India is 120 dollars a year.

Following the judgment of the Indian Supreme Court is natural to ask what are the generics that could take advantage of niche opened by this decision. As reported by the Indian analysts at Bloomberg, it would benefit especially Taj Pharmaceuticals, a leading Indian generic manufacturer among others like Celon Labs, Natco Pharma, Dr. Reddy, Cipla, Glenmark Pharmaceuticals and Ranbaxy.

Some manufacturers of generic imatinib listed on the stock market have gained ground on the Bombay Stock Exchange, which allows you to make a fairly accurate estimate of what the companies in pole position to win market share that Glivec “designer” is intended to surrender in the coming months. In the first place there Natco Pharma, whose title is rebounded by 5.4 per cent in second place Ranbaxy, who scored a +2.7 per cent in third place Cipla, whose stock rose 1 , 2 percent.

This does not preclude other generics, active in other countries of the world, they decide to expand or short to converge on the square in India. In addition to Sandoz, which belongs to the same Novartis, one of the generic drug manufacturers who have imatinib in its portfolio there are Teva and Aurobindo.


According to the WHO, cancer costs the EU countries 124 billion each year. But only 36 percent of the figure is related to medications, hospitalizations, interventions and therapies. Some estimates say that a cancer patient can use the total resources ranging from 50-70 thousand up to 300 thousand euro, taking into consideration in the calculation of the set of diagnoses, hospitalizations, interventions, medications and treatments.

If we take into account an average of 150 thousand euro and to multiply to one million patients in Italy, we spend 150 billion euro for a generation of patients, spread over three to five years average survival.

Figures for the most part the responsibility of the National Health System, which through exemptions, guarantees access in Italy mostly without disbursements to anti-tumor effects. At least up to now, but the crisis is felt and spaces of gratuity is reduced for patients.

Even in Italy there are generic drugs against cancer. The first was launched in 2004 and contained paclitaxel molecule used for the treatment of cancer of the breast and ovaie.L ‘incidence of low cost, however, is still a minority if you think that, overall, these drugs account for about 16 per percent of the domestic market and 8 percent of spending, public and private annual savings of about 300 million euro for the benefit of the NHS. The economic relief is crucial if one considers that the average reduction in price of 60 per cent after the expiry of patents. From New Delhi could get a decisive help.

Notes to Editor

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world.

About EMA
The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.

Food and Drug Administration
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

About Taj Pharmaceuticals Group (India)
Taj Pharmaceuticals Limited is a pharmaceutical company founded and based in India. The company manufactures pharmaceutical formulations and API for India and other countries, owning about 450 brands and 4000 generic licenses. The company was established in 1995 as an enterprise and in 2004 became a public limited company with about $1Bn in sales.

Responsibility Statement
Certain statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that do not describe historical facts and statements that refer or relate to events or circumstances that the mentioned companies “estimates,” “believes,” or “expects” to happen or similar language. The forward-looking statements in this press release are based on the current expectations of the parties engaged and are made only as of the date of this press release and involve certain risks and uncertainties that could cause actual results to differ materially from future results that may be expressed or implied by such forward-looking statements. Unless required by law, no mentioned company undertake any obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

Alchemist Hospital conducted a CME which is based on “Prevention & Treatment of Lifestyle Diseases” with Indian Medical Association, Gurgaon, at hotel Ramada Central, Sector- 44, Gurgaon.

All doctors who are specialist in lifestyle diseases were invited in this CME. Purpose of this CME was to invent new treatments & prevention to save the human life from regular lifestyle diseases.

On this CME doctors discussed about the regular Lifestyle diseases that how to save human life from lifestyle diseases and why do these build up in our life.


This programme started with Introduction which was given by (CEO Alchemist Hospital) Dr.(col.) A. Ganpathy after that Cardiac surgeon Dr. Pramod Mittal, Cardiology lifestyle diseases specialist Dr. Niraj kimar, Orthopedic lifestyle diseases specialist Dr. Neeraj Sharma, Nephrologists Dr. Sashidhar Shree Niwas and Bariatric Surgeon Dr. Vikas Kapoor explained their topic one by one.

Dr. Pramod Mittal said that had done 80% open heart surgery, he also added that CABG (Coronary Artery Bypass Graft) is more beneficial for human life to keep away human life from the heart problems and Dr. Niraj Kumar said, Indians 4 times more than white American, 6 times more than Chinese and 20 times more than Japanese infected with heart diseases and prevalence of heart diseases in urban adults are 7-10 % in north India and 14 % in south India.

Dr. Niraj Kumar said, obesity, weight increasing, hypertension and diabetes are enhancing day to day, cause of this problem smoking, junk food and alcohol. He said that why we are unable to achieve our goal because of lack of Awareness, Changing Life style, under diagnosed, Poor Treatment Compliance and Side effects with commonly used antihypertensive drugs.

Dr. Neeraj Sharma(Orthopedic lifestyle diseases specialist) said, A lifestyle disease associated with the way a person or group of people lives like Backache , Osteoporosis and Arthritis so people should do regular exercise and quit smoking .

Dr. Shashidhar Shree Niwas (Nephrologist) said, various ways to keep the Kidneys Healthy – like we have to, Keep fit and active, Keep regular control of your blood sugar levels, blood lipids and anaemia, Monitor blood pressure, reduce if necessary.

Eat healthy and keep your weight in check and most importanly don’t smoke.

Doctors also gave advice that Red Wine is good for heart instead of any other alcoholic items.On this programme complete Alchemist Hospital team and all doctors of gurgaon were available there.

Twitter Updates


June 2015
« Jan    

Get every new post delivered to your Inbox.

Join 471 other followers